Corrigendum: Triplebody Mediates Increased Anti-Leukemic Reactivity of IL-2 Activated Donor Natural Killer (NK) Cells and Impairs Viability of Their CD33-Expressing NK Subset

Front Immunol. 2018 Oct 8:9:2326. doi: 10.3389/fimmu.2018.02326. eCollection 2018.

Affiliations

¹ Institute for Cellular Therapeutics, IFB-Tx, Hannover Medical School (MHH), Hannover, Germany.
² Department I of Internal Medicine, University Hospital of Cologne, Cologne, Germany.
³ Department of Hematology, Hemostasis, Oncology, and Stem Cell Transplantation, Hannover Medical School (MHH), Hannover, Germany.
⁴ Experimental Tumor Research, Center for Tumor Biology and Immunology, Philipps University Marburg, Marburg, Germany.

Abstract

[This corrects the article DOI: 10.3389/fimmu.2017.01100.].

Keywords: CD19; CD33; ULBP2; acute myeloid leukemia; immunoligands; natural killer cells; natural killer group 2 member D; triplebodies.

Publication types

Published Erratum